Pangea Pharmaceuticals, a U.S.-based pharmaceutical company focused on delivering differentiated, clinically relevant therapies, today announced a strategic commercial partnership with Brillian Pharma, granting Pangea exclusive U.S. commercialization rights to Sdamlo™ (Amlodipine Besylate), NDA 219531, across all approved strengths. The commercial launch and more information will be announced in Q1 2026.

Amlodipine is one of the most widely prescribed medications for the management of high blood pressure and cardiovascular disease, used by millions of patients nationwide. However, many currently available formulations—primarily tablets and alcohol-based or refrigerated liquids—can be difficult for children, older adults, and patients who have trouble swallowing or managing complex medication regimens. Sdamlo™ addresses this gap and supports improved continuity of care and strengthens treatment adherence:

• Powder for oral solution — simply mixed with water
• Alcohol-free and solvent-free
• No refrigeration required — simplified storage and transport
• Flexible and accurate dosing once reconstituted
• Packaged for efficiency in pharmacy and clinical settings

This combination is designed to improve continuity of care across retail pharmacies, specialty, institutional, home health, and long-term care environments.

“This agreement represents another milestone in Pangea’s mission to bring high-value, clinically relevant medicines to patients and caregivers in areas of continued medical need,” said Tony LaViola, Chief Executive Officer of Pangea Pharmaceuticals. “Sdamlo™ is an essential cardiovascular therapy, and with Pangea’s experienced in-house commercial team and established commercialization platform, our integrated channel capabilities—spanning physician engagement, retail access, HUB support, and institutional distribution—position us to efficiently scale adoption and deliver meaningful value to patients, providers, and partners.”

About Pangea Pharmaceuticals

Pangea Pharmaceuticals is a U.S.-based pharmaceutical company focused on acquiring, developing, and commercializing therapies that address unmet or underserved clinical needs across multiple dosage forms—injectables, oral solids, liquid formulations, and specialty delivery platforms. Leveraging a lean, asset-light manufacturing model and a national commercialization infrastructure, Pangea brings mature brands and novel formulations back into meaningful clinical relevance through targeted market engagement and patient-focused execution.

About Brillian Pharma

Brillian Pharma, Inc. is a privately held specialty pharmaceutical company focused on advanced drug delivery platforms and the development of pediatric formulations. The company’s core mission is to increase pediatric access to critical therapeutics by leveraging innovative delivery technologies and clinical development.

For more information about Pangea Pharmaceuticals and its growing portfolio of differentiated therapies, please visit our products page.